Treatment Outcomes for Portal Hypertension Esophageal and Gastric Varices

Assessment of Treatment Outcomes for Esophageal and Gastric Varices Secondary to Portal Hypertension

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07358663

Enrollment

1384

Registered

2026-01-22

Start date

2026-01-20

Completion date

2028-12-31

Last updated

2026-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophagogastric Varices, Portal Hypertension

Keywords

endoscopic treatment, portal hypertension

Brief summary

This study is a single-center, prospective cohort study based on real-world data. Patients with portal hypertension and esophagogastric varices were enrolled and divided into an endoscopic treatment group and a non-endoscopic treatment group (including patients receiving medical therapy, interventional procedures, or surgical treatment) according to whether they underwent endoscopic intervention. Baseline data, serum metabolites, CT imaging and endoscopic images, liver biopsy pathology, and other multi-omics data were integrated for both groups. Patients were followed up to compare adverse events after variceal treatment, including rebleeding and its causes, hepatic encephalopathy, ascites, subsequent treatments (such as regular endoscopic therapy, NSSB, and TIPS), and survival outcomes. Clinical characteristics of portal hypertension attributed to different etiologies, including hepatitis B, autoimmune liver disease, schistosomiasis, hematological disorders, and chemotherapy-induced liver injury, were compared. The efficacy and safety of endoscopic and interventional treatments for esophagogastric varices were evaluated. Factors influencing rebleeding rates among different treatment groups were analyzed, and reasons for inclusion in different groups were discussed.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Clinical diagnosis of portal hypertension with esophagogastric varices. * Underwent abdominal CT and gastroscopy examinations.

Exclusion criteria

* Presence of peptic ulcer, gastric tumor, or other causes of gastrointestinal bleeding confirmed by imaging or gastroscopy. * CT images of inadequate quality or incomplete medical history data.

Design outcomes

Primary

Measure	Time frame	Description
Survival	At 1, 2, 6, and 12 months post-treatment	Survival status

Secondary

Measure	Time frame	Description
Adverse events	At 1, 2, 6, and 12 months post-treatment	Post-treatment adverse events included rebleeding (and its causes), hepatic encephalopathy, and ascites

Countries

China

Contacts

CONTACTXiaoquan Huang, M.D.

huang.xiaoquan@zs-hospital.sh.cn86-18801733835

PRINCIPAL_INVESTIGATORShiyao Chen, Ph.D.

Fudan University

Outcome results